1.53
Hoth Therapeutics Inc stock is traded at $1.53, with a volume of 715.63K.
It is down -3.16% in the last 24 hours and down -4.38% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$1.58
Open:
$1.58
24h Volume:
715.63K
Relative Volume:
0.67
Market Cap:
$20.29M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-1.1591
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
+0.00%
1M Performance:
-4.38%
6M Performance:
+91.06%
1Y Performance:
+103.73%
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HOTH
Hoth Therapeutics Inc
|
1.53 | 20.95M | 0 | -7.51M | -8.02M | -1.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Chart based analysis of Hoth Therapeutics Inc. trendsEntry Point & Smart Investment Allocation Insights - newser.com
Can momentum traders help lift Hoth Therapeutics Inc.Trade Volume Summary & Fast Exit Strategy with Risk Control - newser.com
Will Hoth Therapeutics Inc. stock maintain growth storyStop Loss & Free Weekly Watchlist of Top Performers - newser.com
Measuring Hoth Therapeutics Inc.’s beta against major indicesJuly 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
What candlestick patterns are forming on Hoth Therapeutics Inc.2025 Price Momentum & Risk Controlled Stock Alerts - newser.com
How to forecast Hoth Therapeutics Inc. trends using time seriesMarket Rally & Reliable Breakout Forecasts - newser.com
Is Hoth Therapeutics Inc. stock entering bullish territoryJuly 2025 Institutional & Fast Gain Stock Trading Tips - newser.com
What valuation multiples suggest for Hoth Therapeutics Inc. stockMarket Movers & Fast Entry Momentum Trade Alerts - newser.com
What analysts say about Hoth Therapeutics Inc stockSector ETF Performance & Free High Yield Growth Strategies - earlytimes.in
Hoth Therapeutics shares climb after expanding AI partnership with NVIDIA - MSN
Hoth Therapeutics stock rises after expanding AI initiative with NVIDIA By Investing.com - Investing.com Nigeria
Hoth Therapeutics stock rises after expanding AI initiative with NVIDIA - Investing.com
Hoth Therapeutics rises as it expands AI push with Nvidia licenses - TradingView
Hoth Therapeutics expands AI capabilities with NVIDIA partnership By Investing.com - Investing.com Canada
Hoth Therapeutics expands artificial intelligence initiative, selects NVIDIA AI Enterprise platform - MarketScreener
Hoth Therapeutics expands AI capabilities with NVIDIA partnership - Investing.com
Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform - MarketScreener
Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025 - WV News
Analyzing Hoth Therapeutics Inc. with multi timeframe chartsVolume Spike & Community Verified Swing Trade Signals - newser.com
Best data tools to analyze Hoth Therapeutics Inc. stock2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention - ADVFN
EGFR Inhibitors Induced Skin Disorders Market Research 2025-2035: Epidemiology, Regulations, Pipeline Analysis Featuring Azitra, Hoth Therapeutics, and Lutris PharmaResearchAndMarkets.com - The AI Journal
About Us - FinancialContent
Is Hoth Therapeutics Inc a good long term investmentCandlestick Pattern Analysis & Free Exceptional Risk Adjusted Gains - earlytimes.in
What institutional flow reveals about Hoth Therapeutics Inc.Portfolio Value Summary & High Yield Stock Recommendations - newser.com
EGFR Inhibitors-Induced Skin Disorders Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Lutris Pharma, Hoth Therapeutics, TWi Biotechnology - Barchart.com
Hoth expands HT-001 development with patents for cancer therapy side effects - Investing.com Nigeria
Hoth expands HT-001 development with patents for cancer therapy side effects By Investing.com - Investing.com South Africa
Hoth Therapeutics Expands Patent Portfolio for HT-001 to Target Wider Range of Skin Toxicities - MarketScreener
Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities - WV News
Hoth Therapeutics, Inc. (HOTH) Files EMA Application for Global Expansion of HT-001 Skin Therapy - Yahoo Finance
Chart Watch: Can Hoth Therapeutics Inc stock double in the next year2025 Trade Ideas & Community Verified Watchlist Alerts - خودرو بانک
Bull Run: Will Hoth Therapeutics Inc benefit from rising consumer demandMarket Performance Report & Risk Controlled Stock Pick Alerts - خودرو بانک
New Highs: Whats the MACD signal for Hoth Therapeutics IncWeekly Trend Recap & Proven Capital Preservation Tips - خودرو بانک
Risks Report: Whats the outlook for Hoth Therapeutics Incs sectorWeekly Trading Summary & Daily Price Action Insights - خودرو بانک
Market Review: Is NGVT a momentum stockMarket Weekly Review & Risk Controlled Swing Alerts - khodrobank.com
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):